Return to flip book view

The BCIF aims to raise two million dollars to finance a small-scale clinical trial of a revolutionary new breast implant cover infused with the Doxorubicin (DOX) chemotherapy drug that would provide targeted, local chemotherapy to breast tissue after surgery. In preliminary experiments, this DOX-eluting fiber mat has demonstrated an ability to locally target – and kill – cancer cells and mitigate the major complication of capsular contracture associated with breast reconstruction.Private funding can make this revolutionary local chemotherapy a reality, helping to put women’s health ahead of financial interests.Learn more at bcif.usLearn more at bcif.usThe New Drug Delivery Platform can be Expanded for a Range of Applications• We aim to improve the efficacy of current biomedical devices by using a clinically tested biomaterial with pharmaceutical capabilities and to allow for the development of novel device technologies.• The technology can be expanded to other cancers (e.g. prostate cancer) and other implantable devices with antimicrobials, anti-inflammatory agents, steroids, analgesics, etc.• Medical device development: Ongoing collaboration with the Semmelweis Medical University (Hungary).The Research• The research aims to gather data through a clinical trial on the efficacy of local chemotherapy using a drug-eluting implant cover, a new approach, as compared to traditional treatment methods.• The first target market would be for early stage (I & II) breast cancer patients, later extended for later stage (III+) patients with anticipated reduced side-effects.• The expected improvements in quality of life include a reduction in the large-scale side-effects from traditional, global chemotherapy, including reduced hair loss, nausea, fatigue, etc. Message

Cancer is Diagnosed in Over 350,000 American and Canadian Women Each Year• Breast cancer claims >50,000 American and Canadian lives each year.• Mastectomy with postoperative chemotherapy offers the best rate of survival.• Current tissue expanders and implants for reconstruction are silicone rubber-based and have over 20% complication rates, leading to multiple surgeries.• These implants can be made into healing devices with the drug-eluting covers.• 19% of post-mastectomy patients are currently subject to recurrent cancer(2-3 years average).Components• The polymer family has been used as the drug-eluting coating on coronary stents since their 2004 FDA approval, proving long-term acceptance in the human body. It has been implanted into over 10 million patients in the USA.• Doxorubicin is an FDA-approved cancer drug.Solving the Major Problem with Silicone Rubber Breast ReconstructionA thick, fibrous capsule forms around most implants leading to pain, disfigurement, rupture and requirements for further surgeries.With current breast implants, 35-50% of reconstruction patients require revisional surgery within 6 years. Our preliminary experiments demonstrated loosening the capsule tissue, a potential solution to the capsular contracture problem.Fiber mat cover infused with DOXCapsular Contracture

Cancer is Diagnosed in Over 350,000 American and Canadian Women Each Year• Breast cancer claims >50,000 American and Canadian lives each year.• Mastectomy with postoperative chemotherapy offers the best rate of survival.• Current tissue expanders and implants for reconstruction are silicone rubber-based and have over 20% complication rates, leading to multiple surgeries.• These implants can be made into healing devices with the drug-eluting covers.• 19% of post-mastectomy patients are currently subject to recurrent cancer(2-3 years average).Components• The polymer family has been used as the drug-eluting coating on coronary stents since their 2004 FDA approval, proving long-term acceptance in the human body. It has been implanted into over 10 million patients in the USA.• Doxorubicin is an FDA-approved cancer drug.Solving the Major Problem with Silicone Rubber Breast ReconstructionA thick, fibrous capsule forms around most implants leading to pain, disfigurement, rupture and requirements for further surgeries.With current breast implants, 35-50% of reconstruction patients require revisional surgery within 6 years. Our preliminary experiments demonstrated loosening the capsule tissue, a potential solution to the capsular contracture problem.Fiber mat cover infused with DOXCapsular Contracture

Cancer is Diagnosed in Over 350,000 American and Canadian Women Each Year• Breast cancer claims >50,000 American and Canadian lives each year.• Mastectomy with postoperative chemotherapy offers the best rate of survival.• Current tissue expanders and implants for reconstruction are silicone rubber-based and have over 20% complication rates, leading to multiple surgeries.• These implants can be made into healing devices with the drug-eluting covers.• 19% of post-mastectomy patients are currently subject to recurrent cancer(2-3 years average).Components• The polymer family has been used as the drug-eluting coating on coronary stents since their 2004 FDA approval, proving long-term acceptance in the human body. It has been implanted into over 10 million patients in the USA.• Doxorubicin is an FDA-approved cancer drug.Solving the Major Problem with Silicone Rubber Breast ReconstructionA thick, fibrous capsule forms around most implants leading to pain, disfigurement, rupture and requirements for further surgeries.With current breast implants, 35-50% of reconstruction patients require revisional surgery within 6 years. Our preliminary experiments demonstrated loosening the capsule tissue, a potential solution to the capsular contracture problem.Fiber mat cover infused with DOXCapsular Contracture

The BCIF aims to raise two million dollars to finance a small-scale clinical trial of a revolutionary new breast implant cover infused with the Doxorubicin (DOX) chemotherapy drug that would provide targeted, local chemotherapy to breast tissue after surgery. In preliminary experiments, this DOX-eluting fiber mat has demonstrated an ability to locally target – and kill – cancer cells and mitigate the major complication of capsular contracture associated with breast reconstruction.Private funding can make this revolutionary local chemotherapy a reality, helping to put women’s health ahead of financial interests.Learn more at bcif.usLearn more at bcif.usThe New Drug Delivery Platform can be Expanded for a Range of Applications• We aim to improve the efficacy of current biomedical devices by using a clinically tested biomaterial with pharmaceutical capabilities and to allow for the development of novel device technologies.• The technology can be expanded to other cancers (e.g. prostate cancer) and other implantable devices with antimicrobials, anti-inflammatory agents, steroids, analgesics, etc.• Medical device development: Ongoing collaboration with the Semmelweis Medical University (Hungary).The Research• The research aims to gather data through a clinical trial on the efficacy of local chemotherapy using a drug-eluting implant cover, a new approach, as compared to traditional treatment methods.• The first target market would be for early stage (I & II) breast cancer patients, later extended for later stage (III+) patients with anticipated reduced side-effects.• The expected improvements in quality of life include a reduction in the large-scale side-effects from traditional, global chemotherapy, including reduced hair loss, nausea, fatigue, etc.

The BCIF aims to raise two million dollars to finance a small-scale clinical trial of a revolutionary new breast implant cover infused with the Doxorubicin (DOX) chemotherapy drug that would provide targeted, local chemotherapy to breast tissue after surgery. In preliminary experiments, this DOX-eluting fiber mat has demonstrated an ability to locally target – and kill – cancer cells and mitigate the major complication of capsular contracture associated with breast reconstruction.Private funding can make this revolutionary local chemotherapy a reality, helping to put women’s health ahead of financial interests.Learn more at bcif.usLearn more at bcif.usThe New Drug Delivery Platform can be Expanded for a Range of Applications• We aim to improve the efficacy of current biomedical devices by using a clinically tested biomaterial with pharmaceutical capabilities and to allow for the development of novel device technologies.• The technology can be expanded to other cancers (e.g. prostate cancer) and other implantable devices with antimicrobials, anti-inflammatory agents, steroids, analgesics, etc.• Medical device development: Ongoing collaboration with the Semmelweis Medical University (Hungary).The Research• The research aims to gather data through a clinical trial on the efficacy of local chemotherapy using a drug-eluting implant cover, a new approach, as compared to traditional treatment methods.• The first target market would be for early stage (I & II) breast cancer patients, later extended for later stage (III+) patients with anticipated reduced side-effects.• The expected improvements in quality of life include a reduction in the large-scale side-effects from traditional, global chemotherapy, including reduced hair loss, nausea, fatigue, etc.